JJ
NPCE icon

Johnson & Johnson’s Neuropace NPCE Stock Holding History

Johnson & Johnson’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-55,435
Closed -$879K – 26
2021
Q3 		$879K Buy
+55,435
New +$1.16M 0.08% 19

Other funds holding NPCE

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Johnson & Johnson's NPCE Position: Q4 2021 in Review

Johnson & Johnson sold out of Neuropace (NPCE) in Q4 2021, closing a stake of 55,435 shares — an estimated $879K sold.

Johnson & Johnson first reported a position in NPCE in Q3 2021 and held it in 1 quarter. The position peaked at $879K in Q3 2021. 41 funds tracked by Wall St. Rank hold NPCE as of Q4 2021.

  • Johnson & Johnson reported no remaining Neuropace position as of Q4 2021 after selling out during the quarter.
  • Johnson & Johnson sold 55,435 Neuropace shares in Q4 2021, an estimated $879K.
  • Johnson & Johnson first reported a position in Neuropace in Q3 2021 and held it in 1 quarter.
  • Johnson & Johnson's Neuropace position peaked at $879K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Neuropace as of Q4 2021.

Based on Johnson & Johnson's 13F filing for Q4 2021, filed 14 Feb 2022.